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Abstract
Objective Nitisinone induced hypertyrosinaemia is a concern in patients with Alkaptonuria (AKU). It has been suggested 
that this may alter neurotransmitter metabolism, specifically dopamine and serotonin. Herein mass spectrometry imaging 
(MSI) is used for the direct measurement of 2,4-diphenyl-pyranylium tetrafluoroborate (DPP-TFB) derivatives of monoamine 
neurotransmitters in brain tissue from a murine model of AKU following treatment with nitisinone.
Methods Metabolite changes were assessed using MSI on DPP-TFB derivatised fresh frozen tissue sections directing analysis 
towards primary amine neurotransmitters. Matched tail bleed plasma samples were analysed using LC–MS/MS. Eighteen 
BALB/c mice were included in this study:  HGD−/− (n = 6, treated with nitisinone—4 mg/L, in drinking water);  HGD−/− 
(n = 6, no treatment) and  HGD+/− (n = 6, no treatment).
Results Ion intensity and distribution of DPP-TFB derivatives in brain tissue for dopamine, 3-methoxytyramine, noradrena-
line, tryptophan, serotonin, and glutamate were not significantly different following treatment with nitisinone in HGD −/− 
mice, and no significant differences were observed between  HGD−/− and  HGD+/− mice that received no treatment. Tyrosine 
(10-fold in both comparisons, p = 0.003; [BALB/c  HGD−/− (n = 6) and BALB/c  HGD+/− (n = 6) (no treatment) vs. BALB/c 
 HGD−/− (n = 6, treated)] and tyramine (25-fold, p = 0.02; 32-fold, p = 0.02) increased significantly following treatment with 
nitisinone. Plasma tyrosine and homogentisic acid increased (ninefold, p = < 0.0001) and decreased (ninefold, p = 0.004), 
respectively in  HGD−/− mice treated with nitisinone.
Conclusions Monoamine neurotransmitters in brain tissue from a murine model of AKU did not change following treatment 
with nitisinone. These findings have significant implications for patients with AKU as they suggest monoamine neurotrans-
mitters are not altered following treatment with nitisinone.
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PKU  Phenylketonuria
3-MT  3-methoxytyramine
1 Introduction
Alkaptonuria (AKU, OMIM: 203500) is a rare bi-allelic 
autosomal recessive disorder of the tyrosine metabolic 
pathway, occurring 1 in 100,000–250,000 of the general 
population (Phornphutkul et al. 2002) and arises from a 
congenital deficiency in the enzyme homogentisate-1,2-di-
oxygenase (HGD, E.C.1.12.11.5) (Fig. 1). The biochemi-
cal hallmark of AKU is that circulating concentrations of 
homogentisic acid (HGA) markedly increase, and it is this 
that is thought to be responsible for many of the com-
plications observed (for a detailed review see Ranganath 
et al. 2013). Treatment for this condition is largely based 
on supportive and palliative measures that include pain 
relief and anti-inflammatory medications, dietary pro-
tein restriction and joint replacement (Ranganath et al. 
2013). Currently the drug nitisinone, a competitive inhib-
itor of hydroxyphenylpyruvic acid dioxygenase (HPPD, 
E.C. 1.13.11.27) (Fig. 1), is being evaluated as a poten-
tial treatment (Ranganath et al. 2016; Milan et al. 2017; 
SONIA-2—ClinicalTrials.gov Identifier: NCT01916382). 
This drug acts to move the metabolic block in the tyros-
ine metabolic pathway resulting in a marked reduction in 
the circulating concentration of HGA and a consequen-
tial significant increase in tyrosine, creating a so called 
‘pseudo type-3 Tyrosinaemia’ picture (Suwannarat et al. 
2005; Introne et al. 2011; Olsson et al. 2015; Ranganath 
et al. 2016; Milan et al. 2017; Davison et al. 2018a, b). 
Hypertyrosinaemia has also been well documented in 
patients with Hereditary Tyrosinaemia type-1 (HT1, 
OMIM 276700) that are treated with nitisinone (Lindst-
edt et al. 1992; Zeybek and Zubarioglu 2017; van Ginkel 
et al. 2017).
The metabolic fate of these supraphysiological tyrosine 
concentrations is unknown. It has been proposed in HT1 that 
hypertyrosinaemia may contribute to the neurodevelopmen-
tal delay that is frequently observed in children (McKiernan 
et al. 2015). Several mechanisms have been proposed for 
this, including increased transport of tyrosine into the brain; 
decreased transport of other neutral amino acids into the 
brain (specifically tryptophan); increased central nervous 
system dopamine; decreased central nervous system seroto-
nin, oxidative damage from δ-aminolevulinic acid and succi-
nylacetone or modification of neuronal proteins (Hillgartner 
et al. 2016; Thimm et al. 2011). It has also been suggested 
that altered serotonin metabolism may be due to direct inhi-
bition of tryptophan hydroxylase (TPH; EC 1.14.16.4) activ-
ity by tyrosine, which leads to a reduced biosynthesis of 
serotonin (Thimm et al. 2011).
In AKU there is uncertainty about whether the hyper-
tyrosinaemia may alter neurotransmitter metabolism and 
specifically whether this may lead to depression or altered 
cognition through the mechanisms detailed above. Recently 
Davison et  al. (2018a) concluded that treatment with 
nitisinone is unlikely to cause depression in patients with 
AKU in a study that assessed and urinary neurotransmit-
ter metabolite concentrations, in a cohort of patients with 
AKU. This study did show an increase in urinary 3-meth-
oxytyramine (3-MT, dopamine metabolite) and a decrease in 
urinary 5-hydroxyindole acetic acid (serotonin metabolite) 
following treatment. These changes did not correlate with 
Beck’s depression inventory-II scores. Similar biochemical 
findings were also reported in a study that evaluated different 
doses of nitisinone (0–8 mg daily for 4-weeks) in patients 
with AKU over a 4-week period (Davison et al. 2017).
While previous studies have demonstrated that hypertyr-
osinaemia clearly results in altered peripheral metabolism of 
dopaminergic and serotoninergic neurotransmitter metabo-
lites they are limited as they are not a direct reflection of 
neurotransmitter metabolism in the central nervous system, 
which is directly linked to mood and cognition. Direct meas-
urement of neurotransmitter concentrations in cerebrospinal 
Fig. 1  Tyrosine metabolic pathway—highlighting the site of the 
enzyme defect observed in Phenylketonuria (phenylalanine hydroxy-
lase, PAH EC 1.14.16.1) Alkaptonuria (homogentisate dioxygenase, 
HGD EC 1.13.11.5) and Hereditary Tyrosinaemia Type 1 (maley-
lacetoacetate isomerase, MAI EC 5.2.1.2), and the site of action of 
nitisinone inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD 
EC 1.13.11.27) Adapted from Davison et al. 2017
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fluid and or in the brain are not feasible in this patient group 
owing to their complex musculoskeletal comorbidities.
Herein for the first time we report a direct approach to 
assess whether hypertyrosinaemia effects monoamine neu-
rotransmitter metabolism. Desorption electrospray ionisation 
mass spectrometry imaging (DESI-MSI) was used to meas-
ure the ion intensity and distribution of 2,4-diphenyl-pyra-
nylium tetrafluoroborate (DPP-TFB) derivatives of monoam-
ine neurotransmitters in brain tissue from a murine model 
of AKU (BALB/c  HGD−/−) (Preston et al. 2014) follow-
ing treatment with nitisinone. Chemical charge tagging of 
monoamine neurotransmitters (primary amines) with DPP-
TFB was carried out as previous studies have demonstrated 
significant improvements in signal intensity compared to 
their analysis in native brain tissue (Shariatgorji et al. 2014; 
Shariatgorji et al. 2016; Esteve et al. 2016).
DESI-MSI was employed over other techniques as it 
allows the direct mapping of the distribution and localisa-
tion of multiple molecular species in a single experiment 
(Shariatgorji et al. 2014, 2016). This is in contrast to the 
direct measurement of individual metabolite concentrations 
in brain tissue homogenates, which gives no information 
on distribution and localisation, and more traditional indi-
rect methods like histological, immunochemical and ligand 
based assays (de Jong et al. 2005).
In addition plasma concentrations of homogentisic acid 
and tyrosine were measured using LC–MS/MS, to confirm 
that the murine model employed (1) had the expected bio-
chemical phenotype observed in AKU (i.e. elevated HGA) 
and (2) hypertyrosinaemia was observed following treatment 
with nitisinone.
2  Materials and methods
2.1  Chemicals and reagents
Triethylamine (TEA), hydroxypropyl methylcellulose, poly-
vinylpyrrolidone and perchloric acid were purchased from 
Sigma-Aldrich (Dorset, UK). Water, methanol and trifluoro-
acetic acid (TFA) were obtained from Merck (Hohenbrunn, 
Germany). DPP-TFB was obtained from American Custom 
Chemicals Corporation (San Diego, CA, USA).
2.2  Animal experiments
A murine model of AKU was used for all experiments as 
described previously (Preston et al. 2014). 18 BALB/c mice 
(Fig. 2) (12  HGD−/− and 6  HGD+/−) were used in total. 
Six mice  (HGD−/−) were administered nitisinone (4 mg/L) 
Fig. 2  Summary of experimental workflow involving murine model of AKU, including mouse gender, weight and age; treatment groupings and 
sample collection, processing and storage. SD standard deviation
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through drinking water for one week, the remaining 12 
mice (6  HGD−/− and 6  HGD+/−) received no nitisinone. All 
animals were housed in air conditioned rooms (with a 12 h 
dark/light cycle) at 20 °C and 53% humidity, with access to 
food and water ad libitum at the University of Liverpool. All 
animal experiments complied with the ARRIVE guidelines 
and were carried out in accordance with the U.K. Animals 
(Scientific Procedures) Act, 1986 and associated guidelines, 
EU Directive 2010/63/EU for animal experiments.
2.3  Tail bleeds
Tail bleed samples were collected into Microvettes (Sarstedt, 
Germany) at baseline and after 1 week prior to culling. 
Whole blood samples were centrifuged at 1500×g for 10 min 
at 4 °C and the plasma deproteinised by adding 60% 5.8 M 
perchloric acid (ratio 1:10, perchloric acid:plasma). Sam-
ples were vortexed and centrifuged at 1500×g for a further 
10 min. The supernatant was stored at − 80 °C until analysis 
(Fig. 2).
2.4  Liquid chromatography tandem mass 
spectrometry analysis of mouse plasma
Plasma samples from tail bleeds were analysed for tyrosine, 
nitisinone and HGA using a previously published method 
(Hughes et al. 2015). In brief, samples were analysed for all 
three analytes in a single run on an Agilent 6490 triple quad-
rupole tandem mass spectrometer with Jet-Stream® electro-
spray ionization coupled with an Agilent 1290 Infinity II 
UHPLC pump. Separation was achieved on an Atlantis dC18 
column (100 × 3.0 mm, 3 µm, Waters) maintained at 35 °C. 
Quantification was achieved using a matrix matched seven-
point calibration curve and two product ion transitions for 
each analyte of interest (HGA 167 > 122 and 167 > 108, neg-
ative polarity; tyrosine 182 > 136 and 182 > 91; nitisinone 
330 > 218, positive polarity).The linear measuring range for 
tyrosine, HGA and nitisinone were 60–2000; 15–500 and 
0.5–10 μmol/L, respectively. 2 μL of deproteinized sample 
was diluted 1:1000 with 200 nmol/L 13C6-HGA, 500 nmol/L 
 d4-tyrosine and 2 nmol/L 13C6-nitisinone in 0.1% formic 
acid/deionized water. 10 μL of diluted plasma was injected 
onto the column. Data were acquired using MassHunter LC/
MS Data Acquisition (version B.07.00, Build 7.0). HGA, 
tyrosine and nitisinone concentrations were calculated using 
MassHunter Quantitative Analysis (version B.06.00, Build 
6.0).
2.5  Brain harvesting
Brains were resected from each animal following cervical 
dislocation, and placed into a trough of dry ice cooled iso-
pentane until any effervescence stopped. They were then 
removed using chilled forceps and wrapped in aluminium 
foil and stored at − 80 °C until dissection.
2.6  Tissue processing and derivatisation
Frozen brain tissues were placed into plastic moulds and 
embedded into a matrix composed of 7.5% (w/v) hydroxy-
propyl methylcellulose and 2.5% (w/v) polyvinylpyrro-
lidone. Brains were divided into 3 moulds (n = 6 per mould, 
two brains from each treatment group) to allow axial (n = 6), 
sagittal (n = 6) and coronal (n = 6) sectioning to allow spa-
tially resolved assessment of metabolite changes in brain 
substructures.
Embedded tissues were then cut using a cryo-microtome 
(Leica CM3050S, Leica Microsystems, Wetzlar, Germany) 
to a thickness of 10 μm and thaw mounted onto superfrost 
microscope glass slides (Thermo Scientific, Braunschweig, 
Germany), and dried under a gentle flow of nitrogen. Slides 
were stored at − 80 °C until derivatisation and MSI analysis.
Brain tissues were derivatised as previously described 
(Shariatgorji et al. 2014, 2016) using DPP-TFB (9.2 mg 
DPP-TFB was dissolved in 7.2 mL of 75% methanol alka-
linised with 3.5 μL of TEA to obtain a 1.3 mg/mL derivati-
sation solution). This was applied to dried samples using a 
TM sprayer (HTX Technologies, Chapel Hill, NC) at 75 °C 
in 30 passes using criss-cross pattern [flow rate 80 μL/min, 
nitrogen flow of 10 psi, nozzle speed 1100 mm/min]. Chemi-
cal charge tagging of primary amine functional groups with 
DPP-TFB was done to enhance signal intensity of monoam-
ine neurotransmitters as their analysis has proven difficult 
due to their low-ionization efficiency, spectral interferences 
from tissue components, ion suppression effects and analyte 
in source fragmentation (Shariatgorji et al. 2014; Shariat-
gorji et al. 2016; Esteve et al. 2016).
2.7  Mass spectrometry imaging of mouse brain 
tissue
MSI data were acquired using an OmniSpray-2D DESI 
ion source (Prosolia Inc, Indianapolis, IN, USA) mounted 
onto a Q-Exactive Plus mass spectrometer (Thermo Sci-
entific, Bremen, Germany). A home-built DESI sprayer 
assembly was used. This was based on a previously 
reported design (Takáts et al. 2004) that was modified 
as previously described (Abbassi-Ghadi et  al. 2015). 
The distance between the sprayer and inlet capillary was 
7 mm, the distance between sprayer and sample surface 
was 1.5  mm and the distance between inlet capillary 
and sample surface was < 1 mm. The angle between the 
sprayer and the sample surface was set to 75°, and the 
collection angle between inlet capillary and sample sur-
face was 10°. Methanol/water (95:5 v/v) was used as the 
electrospray solvent, at a flow rate of 1.5 μL/min, and the 
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spray voltage was set to + 4.5 kV. Solvent was delivered 
using a Dionex Ultimate3000 nLC pump (Sunnyvale, CA, 
USA). N4.8 Nitrogen (BOC, Guildford, UK) was used as 
the nebulizing gas at a pressure of 7 bar. An S-Lens RF 
level of 75, capillary temperature of 320 °C and mass 
resolution of 70,000 were employed. Derivatised tissues 
were analysed in positive ion mode using a mass range of 
m/z 250–1000 and an injection time of 150 ms. All images 
were recorded with 100 µm spatial resolution resulting in 
a scan speed of 378.79 µm/s. Compound identities were 
assigned using exact mass only.
2.8  Mass spectrometry imaging data analysis
MSI raw data files were initially converted into cen-
troided.mzML files using MSConvert tool (ProteoWiz-
ard toolbox version 3.0.4043 and then further converted 
into.imzML format using imzML Converter version 1.3, 
RaceabIain et al. 2012), which were then converted to 
SCiLS data format for visualization and statistical analy-
sis of the data in SCiLS Lab v2018b. (Bruker Daltonics, 
Bremen, Germany).
All m/z values for monoamine neurotransmitters were 
extracted with a mass window of less than 0.0052 Da. 
Derivatisation led to the formation of a  [M]+ ion with no 
observable  [M]2+ or [M + Na]+ ions. A peak correspond-
ing to the DPP-TFB derivative was observed with a mass 
shift of + 215.0855 to the exact monoisotopic mass. The 
differences between the theoretical and observed m/z val-
ues of each derivatised compound was < 5 ppm.
2.9  Statistical analysis
A paired t test was used to compare plasma HGA and 
tyrosine concentrations at baseline and 1  week using 
Graphpad Instat (version 3.10, 2009, CA, USA). A p 
value < 0.05 was deemed significant.
Mean intensity and standard deviation of raw m/z sig-
nal intensity for DPP-TFB derivatives of monoamine 
neurotransmitters were extracted from tissue regions of 
interest using SCILs software (SCILs Lab Bruker, version 
2018b).To compare signal intensities for extracted m/z 
values for all compounds an unpaired t-test was used; a p 
value < 0.05 was deemed significant.
3  Results
3.1  LC–MS/MS analysis of plasma homogentisic 
acid and tyrosine
Plasma HGA concentrations were markedly higher in 
BALB/c  HGD−/− mice (AKU mice) at baseline compared to 
 HGD−/+ mice (non-AKU mice). HGA concentrations in the 
 HGD+/− mice were below the lower limit of the measuring 
interval for the assay. Tyrosine concentrations were similar 
at baseline between the three groups studied; the variation 
observed between the three groups is thought to reflect die-
tary intake and normal variation in amino acid metabolism.
Treatment of  HGD−/− mice with nitisinone (mean ± stand-
ard deviation plasma concentration 0.4 ± (0.094) µmol/L) 
resulted in a marked decrease in HGA (ninefold, p = 0.004) 
and increase in tyrosine (ninefold, p = < 0.0001) (Table 1).
3.2  Mass spectrometry imaging 
of neurotransmitters in murine brain tissue
MS images in positive polarity were successfully gener-
ated for all 18 murine brains included in this study. Fig-
ure 3 shows representative sagittal MS images of BALB/c 
mice brains from all three treatment groups. As previously 
described (Shariatgorji et al. 2014, 2016; Esteve et al. 2016) 
chemical charge tagging of primary amines with DPP-TFB 
enabled the detection of dopamine, 3-MT, noradrenaline, 
serotonin, tyrosine, tryptophan and tyramine. It is important 
to note that noradrenaline has the same monoisotopic mass 
as 6-hydroxydopamine (m/z 169.0738), thus chemical charge 
tagging would also theoretically generate a mass shift of 
+ 215.0855 to its exact monoisotopic mass. In this study 
it was assumed the mass shift observed at 384.1575 was 
noradrenaline. This is because it has been hypothesised that 
6-hydroxydopamine is a neurotoxic metabolite of dopamine 
that is only observed in patients with Parkinson’s disease 
that are treated with L-DOPA (Borah and Mohanakumar 
2012). It is proposed that 6-hydroxydopamine aggravates 
Table 1  Plasma tyrosine 
and homogentisic acid 
concentrations at baseline and 
1 week later in a murine model 
of AKU. *p < 0.05 deemed 
significant
Genotype Nitisinone 
treated
Tyrosine (µmol/L, mean ± SD) Homogentisic acid (µmol/L, 
mean ± SD)
Baseline 1-Week p Baseline 1-Week p
HGD−/− (n = 6) Yes 112.3 (21.9) 997.8 (112.7) <0.0001* 197.2 (87.2) 21.6 (4.3) 0.004*
HGD−/− (n = 6) No 92.8 (29.9) 77.6 (16.2) 0.096 215.7 (168.2) 158.2 (89.8) 0.18
HGD+/− (n = 6) No 66.5 (7.9) 62.6 (5.8) 0.27 <3.1 <3.1 NS
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dopaminergic neurodegeneration, and it is this that forms 
the basis of its use in the generation of experimental models 
of Parkinson’s disease (Breese et al. 2005).
Glutamate was also detected, but it is important to note 
that tissue derivatisation is not required for this and native 
sections can be used (Shariatgorji et al. 2016). Using a deri-
vatisation approach allowed analysis of all neurotransmit-
ters in a single analytical run while the embedding approach 
ensured all tissues are treated identically at all times to 
minimise unequal degradation of neurotransmitters. Tissue 
drying was found to further increase stability (Swales et al. 
2018).
Comparisons of m/z ion distribution maps for each 
compound were made between the three groups of mice: 
(1) BALB/c  HGD−/− (n = 6, no treatment) vs. BALB/c 
 HGD−/− (n = 6, treated); (2) BALB/c  HGD+/− (n = 6, no 
treatment) vs. BALB/c  HGD−/− (n = 6, treated); (3) BALB/c 
 HGD−/− (n = 6, no treatment) vs. BALB/c  HGD+/− (n = 6, 
no treatment).
Tyrosine (tenfold, p = 0.003; tenfold, p = 0.003; and 
p = 0.71) and tyramine (25 fold, p = 0.02; 32 fold, p = 0.02; 
p = 0.77) showed significantly more intense signals in mice 
that received treatment with nitisinone (Fig. 3). Signal inten-
sities for tyrosine and tyramine increased in all regions of 
the brains studied. Signals were most intense in the cerebel-
lum, cerebral cortex and hypothalamus for tyrosine, and the 
striatum and cerebellum for tyramine. No differences in ion 
distribution or intensity were observed for the two groups of 
mice that did not receive nitisinone treatment.
Dopamine (striatum of brain only, p = 0.38, p = 0.68, and 
p = 0.47, respectively) and its metabolites 3-MT (striatum 
of brain only, p = 0.67, p = 0.77, and p = 0.94, respectively) 
and noradrenaline (p = 0.41, p = 0.81, and p = 0.54, respec-
tively) did not change significantly following treatment 
with nitisinone. The intensity of the signal for dopamine 
and 3-MT was highest in the striatum, cortical subplate, and 
palladium (Fig. 3). The intensity of the signal for noradrena-
line was more dispersed than that of dopamine and 3-MT, 
and was most intense in the substantia nigra reticulata and 
ventral striatum.
Serotonin (p = 0.54, p = 0.78, and p = 0.64, respectively) 
and its precursor amino acid tryptophan (p = 0.36, p = 0.90, 
Fig. 3  Representative mass spectrometry images of sagittal brain 
tissue sections from the BALB/c mouse. Ion intensity maps of pre-
cursor ions of DPP-TFB derivatives acquired in positive ionisation a 
tyrosine m/z 396.15814; b tyramine m/z 352.16702; c dopamine m/z 
368.16238; d 3-MT m/z 382.18013; e noradrenaline m/z 384.15753; 
f tryptophan m/z 419.1753; g serotonin m/z 396.15854; h gluta-
mate m/z 362.1364. In each panel Left: sagittal brain sections from 
BALB/c mice:  HGD−/− mouse treated with nitisinone (red outline); 
(2)  HGD−/− mouse no treatment (green outline) and (3)  HGD+/− no 
treatment (yellow outline). Right: bar graph of mean (± standard 
deviation) extracted m/z ion intensity for each group (n = 6 in each 
group); ion intensity for dopamine and 3-MT from striatum only, not 
the whole brain section. Scale bar: 6 mm; spatial resolution 100 μm. 
*p < 0.05 deemed significant
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and p = 0.27, respectively), and glutamate (p = 0.89, p = 0.93, 
and p = 0.92, respectively) showed no significant differences 
between mice that received nitisinone and those that did 
not. The signal intensity for serotonin was most intense in 
the substantia nigra reticulata and ventral striatum, while 
its precursor tryptophan and glutamate were found in all 
brain tissues. The latter being most intense in the cerebral 
cortex (Fig. 3).
All monoamine neurotransmitter compounds and related 
metabolites in the two groups of mice that did not receive 
nitisinone treatment were not significantly different (Fig. 3).
4  Discussion
To date the direct consequences of nitisinone induced hyper-
tyrosinaemia on neurotransmitter metabolism in patients 
with AKU has not been reported. Herein for the first time 
we report the direct measurement of DPP-TFB derivatives 
of monoamine neurotransmitters in the brain tissue from a 
murine model of AKU following treatment with nitisinone, 
and corresponding plasma concentrations of HGA and 
tyrosine.
4.1  LC–MS/MS analysis of plasma homogentisic 
acid and tyrosine
Plasma HGA concentrations were markedly higher in 
BALB/c  HGD−/− mice (AKU mice) at baseline compared 
to  HGD−/+ mice (non-AKU mice), this was expected and 
entirely in keeping with the genotype of the mice studied 
(Preston et al. 2014).
Treatment of BALB/c  HGD−/− mice with nitisinone 
resulted in an expected decrease in HGA and increase in 
tyrosine. The changes observed occurred because nitisinone 
is reversible competitive inhibitor of HPPD (Fig. 1). These 
finding confirm that the mice used in this study had the 
biochemical phenotype one would expect in AKU and that 
hypertyrosinaemia was observed following treatment with 
nitisinone.
4.2  Mass spectrometry imaging 
of neurotransmitters in murine brain tissue
Tyrosine and tyramine increased significantly in BALB/c 
 HGD−/− mice treated with nitisinone. No changes in tyrosine 
or tyramine were observed in  HGD−/− and  HGD−/+ mice 
that received no treatment. These novel findings support that 
the changes observed were a consequence of treatment with 
nitisinone. The increase in tyrosine is likely to be the result 
of the ninefold increase in plasma tyrosine, which through 
facilitated diffusion via the LAT-1 transporter (Mastroberar-
dino et al. 1998) will have resulted in increased transport into 
the central nervous system. The large increase in tyramine 
was an unexpected finding, and is a likely consequence of 
the action of aromatic acid decarboxylase, which converts 
tyrosine to tyramine. The physiological role and mechanisms 
of action of this trace amine remain poorly understood in 
mammals. Tyramine is often regarded as a by-product of 
amino acid metabolism with no clear functional relevance 
(Ledonne et al. 2011).
It is reassuring that dopamine did not increase itself and is 
likely to reflect that its synthesis is highly regulated. There is 
a major and minor route for dopamine biosynthesis (Meiser 
et al. 2013). The minor route involves the enzymatic conver-
sion of tyrosine to tyramine via the action of aromatic acid 
decarboxylase, tyramine is then converted to dopamine via 
cytochrome CYP2D6. The major route is via the enzymatic 
conversion of tyrosine to L-DOPA and then to dopamine via 
the actions of tyrosine hydroxylase and then aromatic acid 
decarboxylase. In the face of excess tyrosine and tyramine 
and no change in dopamine one may postulate that one or 
all of the enzymes mentioned are down regulated to limit 
dopamine production when it is not required. A limitation 
of this study is that enzyme activity was not measured. The 
increased catabolism of dopamine to noradrenaline via the 
enzymatic action of dopamine hydroxylase, or to 3-MT via 
the enzymatic action of catechol-o-methyltransferase is 
unlikely as no significant changes were observed in either 
of these compounds following treatment with nitisinone 
(Fig. 3).
Importantly this study did not show any changes in sero-
tonin or tryptophan metabolism in  HGD−/− mice following 
treatment with nitisinone, confirming that hypertyrosinaemia 
does not affect serotonin biosynthesis or metabolism in the 
murine model of AKU studied.
In addition it is reassuring that no significant changes 
were observed in neurotransmitters or their metabolites at 
baseline and 1 week in the  HGD−/− and  HGD−/+ mice that 
received no treatment, supporting that changes that were 
observed were a consequence of treatment with nitisinone.
Whilst there have been no reported investigations of the 
impact of nitisinone induced hypertyrosinaemia on dopa-
minergic and serotoninergic neurotransmitter metabolism in 
AKU, the impact of nitisinone induced hypertyrosinaemia 
on neurotransmitter metabolism has been investigated in 
a mouse model of phenylketonuria (PKU) (Harding et al. 
2014) and HT1 (Hillgartner et al. 2016).
Hillgartner et al. (2016) used a similar dose of nitisinone 
to our group and reported that urinary homovanillic acid 
(dopamine metabolite) increased fourfold following 
nitisinone, but concluded that this was likely to be a reflec-
tion of peripheral breakdown and metabolism and did not 
reflect changes in the central nervous system. In this study 
no direct measurements of dopamine or serotonin were 
made in brain tissue, but they concluded that slower learning 
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and cognitive difference in the mice studied were caused 
by HT1 and not by the treatment with nitisinone. We have 
also reported an increase in a urinary dopamine metabo-
lite (3-MT) following nitisinone treatment in AKU patients 
(Davison et al. 2018a, b, 2017) and are in agreement that 
this is likely to reflect a change in peripheral metabolism of 
catecholamines.
In contrast Harding et al. (2014) used a much higher dose 
of nitisinone (4 mg/mL) than our group (4 mg/L) and as 
expected this led to hypertyrosinaemia; a six-fold increase 
in mean serum tyrosine (256 μmol/L), and a slight but, sig-
nificant increase in brain tyrosine was observed. This was 
however far less than what we observed (ninefold increase 
in mean plasma tyrosine [mean tyrosine 997 µmol/L] and 
tenfold increase in tyrosine in the brain tissue) on a thou-
sand times lower dose of nitisinone. This can be explained 
in large by the metabolic defect in the tyrosine metabolic 
pathway being proximal to the site of nitisinone action in 
PKU and distal in AKU (Fig. 1). In PKU, phenylalanine 
cannot be converted to tyrosine and thus far less accumu-
lates as a consequence of nitisinone inhibiting HPPD, in 
large the observed increase will reflect the accumulation of 
dietary tyrosine.
Harding et al. (2014) also observed that phenylalanine 
decreased by 44% and dopamine increased by 36% in brain 
tissue following nitisinone treatment. Herein no significant 
changes in dopamine in brain from the AKU mouse were 
observed following nitisinone. It has been proposed that the 
lower phenylalanine concentration in brain tissue reduced 
phenylalanine mediated inhibition of tyrosine hydroxylase, 
thus enabling dopamine biosynthesis (Harding et al. 2014). 
Differences may also be accounted for by the fact that total 
brain dopamine concentration was measured by Harding 
et al. (2014) and we only evaluated dopamine in the striatum 
of the brain and analysis was semi-quantitative. The reason 
for this is that the striatum is one of the major dopamine 
producing regions of the brain.
Importantly in the AKU mouse model there was no sig-
nificant difference in brain serotonin in  HGD−/− mice fol-
lowing treatment with nitisinone, or between  HGD−/− and 
 HGD+/− that received no treatment. Serotonin concentra-
tions did not change in PKU animal model following treat-
ment with nitisinone either, but did remain depressed in 
the PKU mice whether they were treated or not, compared 
to wild type mice (Harding et al. 2014). It is thought that 
this was caused by phenylalanine inhibiting the enzyme 
tryptophan hydroxylase, which regulates the rate limiting 
step of serotonin metabolism, and cannot be recovered by 
nitisinone treatment (Harding et al. 2014). Recently Winn 
et al. 2018 provided further support for this hypothesis in a 
study that showed that while blood phenylalanine reduction 
corrects dopamine and serotonin deficiencies in the central 
nervous system; it did not recover the activity of tryptophan 
hydroxylase.
Herein we also showed that glutamate does not change fol-
lowing treatment with nitisinone. The reason for measuring 
this neurotransmitter was that the glutaminergic neurotrans-
mitter system is known to have a close relationship with dopa-
minergic and serotoninergic systems (Andreou et al. 2015). 
Dysregulation of either of the latter may have resulted in a 
compensatory change in the glutaminergic system.
5  Conclusions
Treatment with nitisinone did not affect the ion distribution 
or intensity of the neurotransmitters dopamine, noradrena-
line and serotonin in the AKU mouse brain, suggesting that 
their concentrations do not change. Neurotransmitter pre-
cursor’s tyrosine and tyramine were significantly increased 
following treatment with nitisinone. The significance and 
fate of these metabolites is unknown and requires further 
investigation. These findings have critical importance for 
the use of nitisinone in patients with AKU as they clearly 
demonstrate that nitisinone does not have a direct effect on 
monoamine neurotransmitter metabolism in the central nerv-
ous system of mice with AKU. If these findings translate to 
patients with AKU treated with nitisinone, one can postulate 
that the hypertyrosinaemia occurring following treatment 
with nitisinone does not affect monoamine neurotransmitter 
metabolism and thus is unlikely to result in altered mood or 
cognition.
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